Pacific Biosciences of California, Inc. (PACB) Stock Forecast & Analysis
Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Pacific Biosciences of California, Inc. (PACB:NASDAQ), powered by AI.
- Current Price
- $1.35
- P/E Ratio
- -0.7
- Market Cap
- 405M
- Sector
- Healthcare
What is the Pacific Biosciences of California, Inc. stock price forecast?
Pacific Biosciences of California, Inc. is currently trading at $1.35. View real-time AI analysis on Alpha Lenz.
What is Pacific Biosciences of California, Inc. insider trading activity?
View the latest insider trading data for Pacific Biosciences of California, Inc. on Alpha Lenz.
What is Pacific Biosciences of California, Inc.'s P/E ratio?
Pacific Biosciences of California, Inc.'s P/E ratio is -0.7.
Pacific Biosciences of California, Inc.
NASDAQ · PACB“Pacific Biosciences of California, Inc. trades at a P/E of -0.7 (undervalued) with modest ROE of -213.5%.”
Ask for details →Company Overview
Pacific Biosciences of California, Inc. is a biotechnology company that specializes in developing and commercializing innovative sequencing systems to assist in scientific research and genetic analysis. Its flagship technology, the Single Molecule, Real-Time (SMRT) sequencing platform, enables detailed and accurate exploration of genetic structures, making it invaluable to researchers in genomics, epigenetics, and personalized medicine. This technology is pivotal for advancing understanding in various sectors, including agriculture, healthcare, and environmental biology, by providing comprehensive genome sequencing data. With the rise of personalized and precision medicine, Pacific Biosciences' systems play a critical role in mapping complex genetic information, thus assisting healthcare professionals and researchers in developing targeted therapies and diagnostics. The company is positioned at the forefront of the biotechnology market, leveraging its technological prowess to impact scientific and medical advances on a global scale. Pacific Biosciences continues to contribute to pivotal research worldwide, enabling breakthroughs in numerous fields that rely on high-fidelity, long-read sequencing capabilities.
Company Statistics
FY 2025Profile
Margins
Valuation
Growth (CAGR)
Returns
Financial Health
“Pacific Biosciences of California, Inc. trades at a P/E of -0.7 (undervalued) with modest ROE of -213.5%.”
Ask for details →Frequently Asked Questions
Pacific Biosciences of California, Inc. (ticker: PACB) is a company listed on NASDAQ in the Healthcare sector (Medical Devices). It has approximately 575 employees. Market cap is $405M.
The current price is $1.35 with a P/E ratio of -0.74x and P/B of 75.7x.
ROE is -213.45% and operating margin is -348.46%. Annual revenue is $160M.